InsidersTradesSigma
Track the VERTEX PHARMACEUTICALS INC / MA stock price and the full directors' dealings record of the company, a listed issuer based in United States. Shares trade on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, VERTEX PHARMACEUTICALS INC / MA has recorded 86 public disclosures. Market capitalisation: €137.3bn. The latest transaction was filed on 31 August 2026 (Don). Among the most active insiders: Bozic Carmen. All data is openly available.
86
Insider Decl.
n/a
Thresholds
€2m
2 ops.
Buy Volume
€12m
14 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate VERTEX PHARMACEUTICALS INC / MA Buy (bullish), based on 25 analysts. Average price target: US$563.12.
53Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 7,327 of 29,056 companies
63.9
score / 100
Value38
Quality89
FCF yld2.3%
Earn yld2.9%
EV/EBITDA28.8x
ROE24%
Gross mgn86%
Net mgn33%
Debt/EBITDA0.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 31 August 2026
Declarations86 total
6,000 shares0Common StockSEC:0000875320-26-000261:0
8,251 shares0Common StockSEC:0000875320-26-000251:0
8,251 shares0Common StockSEC:0000875320-26-000253:0
1,541 shares@ US$519.000.0007% mcap100.0% of flowCommonSEC144:0001959173-26-005057
1,500 shares@ US$524.990.0007% mcap100.0% of flowCommonSEC144:0001959173-26-005073
596 shares@ US$482.500.0002% mcap4.9% of flowCommonSEC144:0001959173-26-004906
1,020 shares@ US$462.170.0004% mcap7.4% of flowCommonSEC144:0001959173-26-004764
4,062 shares@ US$450.000.0015% mcap22.0% of flowCommonSEC144:0001959173-26-004654
1,745 shares@ US$450.000.0006% mcap8.6% of flowCommonSEC144:0001959173-26-004391
2,329 shares@ US$481.79100.0% of flowCommon StockSEC:0000875320-26-000140:0
2,633 shares@ US$498.4224.7% of flowCommon StockSEC:0000875320-26-000138:0
2,437 shares@ US$475.3021.8% of flowCommon StockSEC:0000875320-26-000136:0
400 shares@ US$479.751.3% of flowCommon StockSEC:0000875320-26-000129:0
2,329 shares@ US$480.3119.2% of flowCommon StockSEC:0000875320-26-000127:0
357 shares@ US$483.3612.4% of flowCommon StockSEC:0000875320-26-000125:0
3,547 shares@ US$485.1118.8% of flowCommon StockSEC:0001242825-26-000002:0
1,744 shares@ US$485.118.9% of flowCommon StockSEC:0000875320-26-000122:0
1,627 shares@ US$485.119.1% of flowCommon StockSEC:0000875320-26-000120:0
1,518 shares@ US$485.1110.4% of flowCommon StockSEC:0000875320-26-000118:0
873 shares@ US$485.117.9% of flowCommon StockSEC:0000875320-26-000116:0
4,981 shares@ US$485.1116.7% of flowCommon StockSEC:0000875320-26-000114:0
582 shares@ US$485.1114.8% of flowCommon StockSEC:0000875320-26-000112:0
1,453 shares@ US$485.1112.1% of flowCommon StockSEC:0000875320-26-000110:0
25 of 86 declarations
关于 VERTEX PHARMACEUTICALS INC / MA
Vertex Pharmaceuticals Incorporated 是一家总部位于美国的生物制药公司，在美国纳斯达克上市（股票代码：VRTX）。该公司成立于 1989 年，总部设在马萨诸塞州波士顿，全球总部位于波士顿，国际中心设在伦敦。Vertex 已成为治疗严重疾病（尤其是囊性纤维化 (CF)）的领先开发商之一。该公司将高利润的商业基础与旨在随着时间推移扩大 CF 以外收入的长期研发战略相结合。([sec.gov](https://www.sec.gov/Archives/edgar/data/875320/000087532025000213/ex-991_q22025.htm?utm_source=openai)) Vertex 凭借一系列同类首创和同类最佳的 CF 药物建立了其特许经营权，这些药物旨在解决疾病的潜在生物学问题。其上市产品组合包括 TRIKAFTA/KAFTRIO（公司最大的收入驱动因素），以及 KALYDECO、ORKAMBI 和 SYMDEKO/SYMKEVI。最近，Vertex 通过 ALYFTREK、CASGEVY 和 JOURNAVX 扩大了其商业基础，标志着向更加多元化的商业模式的重要转变。2025 年，管理层强调 TRIKAFTA/KAFTRIO 继续支撑业绩，而 ALYFTREK、CASGEVY 和 JOURNAVX 开始贡献可观的增量销售额。([sec.gov](https://www.sec.gov/Archives/edgar/data/0000875320/000087532026000056/vrtx-20251231.htm?utm_source=openai)) 从竞争角度来看，Vertex 在 CF 领域拥有异常强大的护城河。它拥有深厚的科学专业知识、在该疾病领域的领先商业地位以及竞争对手难以复制的大量监管和开发壁垒。尽管如此，投资案例越来越倾向于多元化：该公司不再仅仅是一个 CF 故事，但其 CF 特许经营权仍然是核心盈利引擎。投资者还在关注 Vertex 在急性疼痛和遗传疾病方面的产品线，这可能会扩大其潜在市场并降低产品集中风险。([sec.gov](https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/vrtx-20251231.htm?utm_source=openai)) 从地理上看，Vertex 在美国、欧洲和选定的其他市场拥有广泛的运营足迹。其办事处和职能部门已扩展到美国以外的德国、巴西、印度和爱尔兰，支持商业化、临床开发、制造和监管活动。这种国际结构对于产品发布和公司的全球临床足迹都非常重要。([sec.gov](https://www.sec.gov/Archives/edgar/data/1806837/000110465926019165/verx-20251231x10k.htm?utm_source=openai)) 最近的里程碑巩固了公司的增长轨迹。Vertex 报告称，2025 年总收入为 12.0 billion 美元，同比增长 9%，并预计 2026 年收入为 12.95 billion 至 13.1 billion 美元，管理层预计非 CF 产品将贡献 500 million 美元或更多。该公司还继续推出 ALYFTREK 和 JOURNAVX，同时扩大 CASGEVY，这标志着从单一疾病巨头向多特许经营生物技术平台的战略转变。([sec.gov](https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/vrtx-20251231.htm?utm_source=openai))
